Normal view

Received — 14 October 2025 ⏭ Most Recent Articles: Clinical Epigenetics

Most Recent Articles: Clinical Epigenetics
Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT Ya-Xue Wu, Chao-Ling Wan, Kai-Wen Tan, Yang Zhang, Yan-Ming Zhang, Hao Zhang, De-Pei Wu, Su-Ning Chen, Ying Wang, Xiao Ma, Hai-Ping Dai, Chong-Sheng Qian, Shan-Shan Jiang, Hai-Yan Bao, Xiao-Hui Hu, Zheng Li&hellip
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is potentially the only curative option for high-risk acute myeloid leukemia (AML) patients. However, disease relapse remains the principal cause ...
13 October 2025 at 08:00

Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT

Most Recent Articles: Clinical Epigenetics

By: Ya-Xue Wu, Chao-Ling Wan, Kai-Wen Tan, Yang Zhang, Yan-Ming Zhang, Hao Zhang, De-Pei Wu, Su-Ning Chen, Ying Wang, Xiao Ma, Hai-Ping Dai, Chong-Sheng Qian, Shan-Shan Jiang, Hai-Yan Bao, Xiao-Hui Hu, Zheng Li&hellip

13 October 2025 at 08:00

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is potentially the only curative option for high-risk acute myeloid leukemia (AML) patients. However, disease relapse remains the principal cause ...

Most Recent Articles: Clinical Epigenetics
Clinical cancer epigenetics
13 October 2025 at 08:00

Clinical cancer epigenetics

Most Recent Articles: Clinical Epigenetics

13 October 2025 at 08:00